MedTrace Logo

Impact of Interferon Free Regimens in Patients With Chronic HCV and Successfully Treated HCC

NCT02771405 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 150

Last updated 2026-04-13

No results posted yet for this study

Summary

The study will recruit 150 patients with HCV related HCC ,after HCC treatment the patients will undergo treatment with different regimens of DAAs.

Conditions

Interventions

DRUG

Sofosbuvir

Sofosbuvir 400 mg orally once daily

DRUG

Ribavirin

Ribavirin (RBV) 200 mg tablets administered orally in a divided daily dose (\< 75 kg = 1000 mg and ≥ 75 kg = 1200 mg)

DRUG

Simeprevir

Simeprevir 150 mg orally once daily

DRUG

daclatasvir

Daclatasvir 60 mg orally once daily

DRUG

Ledipasvir

Ledipasvir 90 mg orally once daily

Sponsors & Collaborators

  • Cairo University

    collaborator OTHER

  • National Hepatology & Tropical Medicine Research Institute

    lead OTHER_GOV

Principal Investigators

  • Gamal Esmat, MD. · Cairo University

  • Aisha El Sharkawy, MD · Cairo University

  • Mohamed Hassany, MD · National Hepatology & Tropical Medicine Research Institute (NHTMRI)

  • Mai Mehrez, MD. · National Hepatology & Tropical Medicine Research Institute (NHTMRI)

  • Amr Maged · National Hepatology & Tropical Medicine Research Institute (NHTMRI)

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-03-31
Primary Completion
2017-12-31
Completion
2018-01-31

Countries

  • Egypt

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02771405 on ClinicalTrials.gov